Loading...
•
Apr 30
Engene Q2 2025 Earnings Report
enGene reported a net loss in Q2 2025 driven by a substantial rise in R&D expenses related to its LEGEND trial.
Key Takeaways
enGene saw a significant increase in operating expenses in Q2 2025, resulting in a net loss of $25.8 million. The company emphasized progress in its pivotal LEGEND trial and reaffirmed its cash runway into 2027.
Net loss widened to $25.8 million due to increased R&D investment
EPS came in at -$0.51 compared to -$0.38 a year ago
Cash, cash equivalents, and marketable securities stood at $251.5 million
Company remains on track for a BLA filing in mid-2026 for detalimogene
Engene
Engene
Forward Guidance
enGene expects continued progress in its LEGEND trial with preliminary data updates in 2H 2025 and is targeting a BLA submission by mid-2026.
Positive Outlook
- Strong enrollment in LEGEND study
- EMA feedback supports conditional marketing application
- BLA filing timeline remains on track
- Cash runway extended into 2027
- Recognition as Biotech Company of the Year
Challenges Ahead
- Increased R&D and G&A expenses leading to larger net loss
- No reported revenue in the quarter
- Operational dependency on trial milestones
- Reliance on interest income to offset losses
- No new commercial products yet launched